Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Total Liabilities: €187.3 Mil (As of Dec. 2025)


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
79 GF Score
Price €5.70
GF Value €3.30
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 +10.68% 79 Total Liabilities is €187.3 Mil as of Dec. 2025. GuruFocus rates FRA:I54 with a GF Score™ of 79/100 and a GF Value™ of €3.30 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities for the quarter that ended in Dec. 2025 was €187.3 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly Total Liabilities declined from Dec. 2024 (€206.82 Mil) to Jun. 2025 (€192.16 Mil) and declined from Jun. 2025 (€192.16 Mil) to Dec. 2025 (€187.32 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual Total Liabilities declined from Dec. 2023 (€213.06 Mil) to Dec. 2024 (€206.82 Mil) and declined from Dec. 2024 (€206.82 Mil) to Dec. 2025 (€187.32 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 146.01 223.28 213.06 206.82 187.32

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 213.06 216.15 206.82 192.16 187.32
FRA:I54
79GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=112.801+(43.254+10.008
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+21.26)
=187.3

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=451.585-264.263
=187.3

Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=112.801+(43.254+10.008
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+21.26)
=187.3

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=451.585-264.263
=187.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €187.3 Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Total Liabilities of €187.3 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Biocytogen Pharmaceuticals (Beijing) Co and its competitors.
Is Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Total Liabilities is €187.3 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities of €187.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Total Liabilities is €187.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.30, compared to a current price of €5.70 — trading 72.7% above its estimated fair value. The current Total Liabilities is €187.3 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Total Liabilities is €187.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €5.70 is trading 72.7% above its estimated GF Value™ of €3.30. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for FRA:I54:

  • Total Liabilities: €187.3 Mil
  • GF Value™: €3.30 vs. price of €5.70 (72.7% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
79GF Score

Get the complete analysis for FRA:I54

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.70
Price
€3.30
GF Value